- Pfizer Inc beat analysts' estimate for adjusted profit on Tuesday, helped by strong demand for its pneumonia vaccine Prevnar and breast cancer drug Ibrance, while also reporting an $11 billion gain from the new tax law.
Pfizer beats by $0.06, reports revs in-line; guides FY18 EPS above consensus, revs midpoint above consensus
- Reports Q4 (Dec) earnings of $0.62 per share, excluding non-recurring items, $0.06 better thanthe Capital IQ Consensus of $0.56; revenues rose 0.6% year/year to $13.7 bln vs the $13.67 bln Capital IQ Consensus.
- Co issues upside guidance for FY18, sees EPS of $2.90-3.00, excluding non-recurring items, vs. $2.78 Capital IQ Consensus Estimate; sees FY18 revs of $53.5-55.5 bln vs. $53.82 bln Capital IQ Consensus Estimate.
- In 2018, Pfizer anticipates quarterly dividend payments of $0.34 per share of common stock in addition to $5.0 billion of share repurchases. Excluding the revenues for HIS in the prior-year quarter and the favorable impact of foreign exchange, fourth-quarter 2017 revenues increased by $240 million, or 2% operationally.
- Co anticipates Repatriation Tax Liability of Approximately $15 Billion, Payable to the U.S. Treasury.
No comments:
Post a Comment